Expertise in
13
conditions

Sebastian Giebel

Gliwice Branch, 
Gliwice, SL, PL 
Expertise in
13
conditions
Gliwice Branch, 
Gliwice, SL, PL 

Overview

Sebastian Giebel practices practicing medicine in Gliwice, Poland.

Mr. Giebel is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Graft.

He is actively involved in clinical research, co-authoring 247 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Gliwice Branch, Gliwice, SL, Poland
Other Locations
Maria Sklodowska Curie National Research Institute of Oncology Gliwice Branch
Gliwice, SL, Poland
Gliwice Branch, Gliwice, SL 44102, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Drug
Study Drugs: Zanubrutinib, Bendamustine, Rituximab, Venetoclax
Study Phase: Phase 3
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2025
Intervention Type: Drug
Study Drugs: Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Study Phase: Phase 3
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
Enrollment Status: Completed
Publish Date: January 16, 2025
Intervention Type: Drug
Study Drug: Acalabrutinib
Study Phase: Phase 2
A Phase II Trial on Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients Progressing or Relapsed After Prior R-CHOP Treatment Not Suitable for Autologous Stem Cell Transplant
A Phase II Trial on Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients Progressing or Relapsed After Prior R-CHOP Treatment Not Suitable for Autologous Stem Cell Transplant
Enrollment Status: Completed
Publish Date: December 27, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

247 Total Publications

Correction: Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Correction: Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Journal: Bone marrow transplantation
Published: August 31, 2026

Frequently Asked Questions about Sebastian Giebel

Is Sebastian Giebel a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Sebastian Giebel is classified as an Elite expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Sebastian Giebel participate in research or clinical trials?

Yes. Sebastian Giebel has published 247 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Sebastian Giebel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Giebel's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 30 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile